预防性颅脑照射在不同脑转移风险局限期小细胞肺癌患者中的作用:多中心回顾性研究
该多中心回顾性研究纳入498例根治性放化疗后达CR/PR的局限期小细胞肺癌(LS-SCLC)患者,基于年龄、SER、血红蛋白、PNI、ProGRP和NSE构建脑转移(BM)风险列线图并分层。低风险组PCI与非PCI组BM发生率、OS、PFS均无显著差异;高风险组PCI显著降低BM发生率并改善PFS,但OS无显著差异。
要点
- 列线图预测2年IPFS的AUC在训练、内部验证和外部队列分别为0.738、0.811和0.726。
- 低风险组PCI与非PCI组BM发生率(p=0.220)、OS(p=0.679)、PFS(p=0.616)均无显著差异。
- 高风险组PCI显著降低BM发生率(p<0.0001)并改善PFS(p=0.032),OS无显著差异(p=0.778)。
核心结论
- PCI未改善高或低脑转移风险患者的OS,但显著降低高风险患者的BM发生率并延长PFS。
研究设计与样本
- 多中心回顾性研究纳入3个中心498例根治性放化疗后达CR/PR的LS-SCLC患者。
- 通过单因素和多因素分析筛选BM相关因素构建列线图,据此将患者分为高风险和低风险组。
主要发现
- 列线图包含年龄、SER、血红蛋白、PNI、ProGRP和NSE,预测2年IPFS的AUC在训练、内部验证和外部队列分别为0.738、0.811和0.726。
- 低风险组PCI与非PCI组BM发生率(p=0.220)、OS(p=0.679)、PFS(p=0.616)均无显著差异。
- 高风险组PCI较非PCI组显著降低BM发生率(p<0.0001)并改善PFS(p=0.032),OS无显著差异(p=0.778)。
- 倾向性评分匹配分析显示相似结果。
关键数值与推荐
- 列线图预测2年IPFS的AUC:训练队列0.738,内部验证队列0.811,外部验证队列0.726。
- 低风险组BM发生率PCI vs 非PCI p=0.220,OS p=0.679,PFS p=0.616。
- 高风险组BM发生率PCI vs 非PCI p<0.0001,PFS p=0.032,OS p=0.778。
临床怎么用
- 对于根治性放化疗后达CR/PR的LS-SCLC患者,可根据列线图风险分层评估脑转移风险。
- 高风险患者接受PCI可能降低BM发生率并改善PFS,但未改善OS。
- 低风险患者接受PCI未显示BM发生率、OS或PFS获益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the value of prophylactic cranial irradiation (PCI) in patients with limited-stage small cell lung cancer (LS-SCLC) at different risks of brain metastasis (BM). MATERIALS AND METHODS: A retrospective study included 498 LS-SCLC patients from three centers who achieved complete or partial response (CR/PR) after radical chemoradiotherapy. A nomogram was developed using significant factors associated with BM, identified through univariate and multivariate analyses. Patients were stratified into high- and low-risk groups based on risk scores. The incidence of BM was compared between patients with and without PCI in different risk-stratified populations using the log-rank test. RESULTS: The nomogram included age, start of treatment to the end of radiotherapy (SER), hemoglobin, prognostic nutritional index (PNI), ProGRP, and NSE. The area under the receiver operating characteristics (AUC) of the nomogram for predicting the 2-year probability of intracranial progression-free survival (IPFS) were 0.738, 0.811, and 0.726 in the training, internal validation, and external validation cohorts, respectively. In the low-risk group, no significant differences were observed in BM incidence (p = 0.220), OS (p = 0.679), or PFS (p = 0.616) between PCI and non-PCI groups. In the high-risk group, PCI significantly reduced BM incidence (p < 0.0001) and improved PFS (p = 0.032), while no significant differences were found in OS (p = 0.778). Propensity score-matching analysis showed similar results. CONCLUSION: PCI did not improve OS in patients regardless of high or low risk of BM. However, PCI did significantly reduce the incidence of BM and prolong PFS in patients at a high risk of BM.
引用
- Li X, Lu S, Lv J, et al. The role of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer at different risks of brain metastasis: A multicenter retrospective study. Radiother Oncol. 2025. PMID: 40254167. doi:10.1016/j.radonc.2025.110897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。